Find in Library

Cyclin-Dependent Kinase Inhibitor 2A/B (<i>CDKN2A/B</i>) homozygous deletion was a significant prognostic factor for gliomas and affected the treatment strategy. However, the radiomic features of <i>CDKN2A/B</i> homozygous deletion in gliomas have not been developed, and whether the radiomic features and molecular subgroups can provide prognostic value in low-grade gliomas (LGGs) has yet to be studied. Thus, this study aimed to develop a predictive model of <i>CDKN2A/B</i> in gliomas and investigate the prognostic value of this biomarker and radiomic features in isocitrate dehydrogenase (<i>IDH</i>)-mutant LGGs. First, we developed the predictive model of <i>CDKN2A/B</i> homozygous deletion in 292 patients. The results revealed that radiomic features predict <i>CDKN2A/B</i> homozygous deletion with high accuracy and reliability. Subsequently, the prognostic survival models of 104 patients (<i>IDH</i>-mutant LGGs) were established, which provided an essential value for prognostic evaluation and indicated that <i>CDKN2A/B</i> homozygous deletion can be used as an independent predictor of prognosis in LGGs.